Takeda along with subsidiary Millennium has announced the initiation of Phase II clinical trials for TAK-700, a new treatment for patients with advanced prostate cancer.
TAK-700 is a non-steroidal androgen synthesis inhibitor that has been shown to suppress the production of androgen in the testes and adrenal glands during preclinical studies.
Millennium chief medical officer Nancy Simonian said that TAK-700 is the first drug candidate in the company's prostate programme to advance to Phase II clinical trials.
"We are pleased to see the progress of this compound, and we are striving to develop drugs that will fulfill the unmet medical need for prostate cancer," Simonian said.
The open-label, multiple-dose study will examine the safety and effectiveness of TAK-700 in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
The primary endpoints of the study are safety and tolerability as well as secondary measures to include efficacy, pharmacokinetic and pharmacodynamic endpoints.